The post-operative Pain therapeutics pipeline comprises approximately 39 drug candidates in different stages of development. Post-operative pain is one of the most common problem experienced by a person after any surgery. The intensity of pain can vary from acute to chronic depending upon the time it lasts. It starts when pain receptors activate an electrical signal that travels to the spinal cord. The spinal cord then transmits the signal to the brain. It involves the interaction of various chemicals, known as neurotransmitters, in the body, which together act to produce the sensation of pain in a person.
Innocoll Holdings plc is using CollaRx technology platform for the development of INL-001 for the treatment of post-operative pain. The CollaRx technology platform produces a lyophilized porous matrix of purified collagen that can be implanted at the time of surgery or applied topically to chronic or acute traumatic wounds. The CollaRx matrices are biodegradable and bio-resorbable. The in vivo release of drugs incorporated into the CollaRx matrix takes place via a combination of dissolution, diffusion and the interactive characteristics of the active drug and the formulation that can be modified to affect controlled release.
The research also found that various companies are developing their drug candidates as small molecule in the post-operative pain therapeutics pipeline.
Some of the key players developing drugs for post-operative pain include DURECT Corporation, Elite Pharmaceuticals, Inc., Cara Therapeutics, Inc. and others.
News Courtesy : P&S Market Research
Tagged: Post-Operative Pain Therapeutics, Post-Operative Pain Therapeutics 2017, Post-Operative Pain Therapeutics Analysis, Post-Operative Pain Therapeutics Pipeline, postoperative pain management, postoperative pain management nursing